GIOSTAR has platform technology of developing autologus peripheral mononuclear cells (PBMC’s) into dendritic cells using patient’s blood and tumor cells. At GIOSTAR we offer Dendritic cell (DC) immunotherapy for solid tumors primarily prostate, breast, hepato-cellular carcinoma (HCC), renal, colon, colo-rectal, Glio-blastoma- multiforme (GBM), oral, lung and ovarian cancer. The precursor cells are collected from patients, culture in highly sterile biosafety lab and infuse back through I.V. administration. The process is completely autologus. Once inside body, mature dendritic cells develop antitumor activity through effector T cells. T cells multiply in number, interact and directly kill tumor cells.
Thus with our standardized, broad based and holistic approach, it is now possible to obtain noticeable improvements in cancer patients, in the symptoms as well as their functional abilities via Cancer Cell Therapy.